Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 2/20 | 0.42 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 6/20 | 0.41 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.40 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.40 |
| ▸ | GRIA4 | P48058 | 4/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | GRIA1 | P42261 | 3/20 | 0.38 |
| ▸ | GRIA2 | P42262 | 3/20 | 0.38 |
| ▸ | GRIA3 | P42263 | 3/20 | 0.38 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18659740 | 0.99 | GRIK1 (0.43) | GRIK1GRIK2CYP19A1SLC1A2SLC1A1 | |
| SCHEMBL19505363 | 0.99 | GRIK1 (0.43) | GRIK1GRIK2CYP19A1SLC1A2SLC1A1 | |
| SCHEMBL20913893 | 0.79 | EPHX2 (0.51) | GRIA4 | |
| SCHEMBL20913891 | 0.79 | EPHX2 (0.51) | GRIA4 | |
| SCHEMBL23220476 | 0.79 | EPHX2 (0.51) | GRIA4 | |
| SCHEMBL17618924 | 0.77 | CYP1A2 (0.45) | GRIK1GRIA4GRIA1GRIA2GRIA3 | |
| SCHEMBL19412791 | 0.73 | GRIA4 (0.37) | GRIK1GRIK2CYP19A1SLC1A2SLC1A1 | |
| SCHEMBL10059442 | 0.72 | GRIA4 (0.49) | GRIK1GRIA4GRIA1GRIA2GRIA3 | |
| SCHEMBL19412792 | 0.72 | GRIA4 (0.40) | GRIK1GRIK2SLC1A2SLC1A1GRIA4 | |
| SCHEMBL10059980 | 0.71 | GRIA4 (0.54) | GRIK1GRIK2GRIA4GRIA1GRIA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200290982-A1 | METAL/RADIOMETAL-LABELED PSMA INHIBITORS FOR PSMA-TARGETED IMAGING AND RADIOTHERAPY | THE JOHNS HOPKINS UNIVERSTY | 2020-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200290982-A1 | METAL/RADIOMETAL-LABELED PSMA INHIBITORS FOR PSMA-TARGETED IMAGING AND RADIOTHERAPY | PSMA6, PSMA1, UTS2R | GRIK1 1138/4885GRIK2 2170/4885CYP19A1 4713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.